BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF V600E by allele-specific real-time PCR (AS-PCR). Positive results were confirmed...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Cancer J
Egile Nagusiak: Rustad, E H, Dai, H Y, Hov, H, Coward, E, Beisvag, V, Myklebost, O, Hovig, E, Nakken, S, Vodák, D, Meza-Zepeda, L A, Sandvik, A K, Wader, K F, Misund, K, Sundan, A, Aarset, H, Waage, A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2015
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382665/
https://ncbi.nlm.nih.gov/pubmed/25794135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.24
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak